137 related articles for article (PubMed ID: 15336697)
1. Modulation of transcriptional sensitivity of mineralocorticoid and estrogen receptors.
Wang Q; Anzick S; Richter WF; Meltzer P; Simons SS
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):197-210. PubMed ID: 15336697
[TBL] [Abstract][Full Text] [Related]
2. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties.
Giannoukos G; Szapary D; Smith CL; Meeker JE; Simons SS
Mol Endocrinol; 2001 Feb; 15(2):255-70. PubMed ID: 11158332
[TBL] [Abstract][Full Text] [Related]
3. Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors.
Wang Q; Blackford JA; Song LN; Huang Y; Cho S; Simons SS
Mol Endocrinol; 2004 Jun; 18(6):1376-95. PubMed ID: 15016838
[TBL] [Abstract][Full Text] [Related]
4. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.
Shibata H; Spencer TE; Oñate SA; Jenster G; Tsai SY; Tsai MJ; O'Malley BW
Recent Prog Horm Res; 1997; 52():141-64; discussion 164-5. PubMed ID: 9238851
[TBL] [Abstract][Full Text] [Related]
5. Role of activation function domain-1, DNA binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid receptor-antagonist complexes.
Cho S; Blackford JA; Simons SS
Biochemistry; 2005 Mar; 44(9):3547-61. PubMed ID: 15736964
[TBL] [Abstract][Full Text] [Related]
6. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression.
Szapary D; Huang Y; Simons SS
Mol Endocrinol; 1999 Dec; 13(12):2108-21. PubMed ID: 10598585
[TBL] [Abstract][Full Text] [Related]
7. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL
Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586
[TBL] [Abstract][Full Text] [Related]
8. Modulation of induction properties of glucocorticoid receptor-agonist and -antagonist complexes by coactivators involves binding to receptors but is independent of ability of coactivators to augment transactivation.
He Y; Szapary D; Simons SS
J Biol Chem; 2002 Dec; 277(51):49256-66. PubMed ID: 12376547
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid receptor ligand binding domain is sufficient for the modulation of glucocorticoid induction properties by homologous receptors, coactivator transcription intermediary factor 2, and Ubc9.
Cho S; Kagan BL; Blackford JA; Szapary D; Simons SS
Mol Endocrinol; 2005 Feb; 19(2):290-311. PubMed ID: 15539428
[TBL] [Abstract][Full Text] [Related]
10. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor.
Zhang X; Jeyakumar M; Petukhov S; Bagchi MK
Mol Endocrinol; 1998 Apr; 12(4):513-24. PubMed ID: 9544987
[TBL] [Abstract][Full Text] [Related]
11. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
Jackson TA; Richer JK; Bain DL; Takimoto GS; Tung L; Horwitz KB
Mol Endocrinol; 1997 Jun; 11(6):693-705. PubMed ID: 9171233
[TBL] [Abstract][Full Text] [Related]
12. Corepressor binding to progesterone and glucocorticoid receptors involves the activation function-1 domain and is inhibited by molybdate.
Wang D; Simons SS
Mol Endocrinol; 2005 Jun; 19(6):1483-500. PubMed ID: 15774497
[TBL] [Abstract][Full Text] [Related]
13. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
14. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members.
Kraichely DM; Sun J; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 2000 Oct; 141(10):3534-45. PubMed ID: 11014206
[TBL] [Abstract][Full Text] [Related]
15. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.
Smith CL; Nawaz Z; O'Malley BW
Mol Endocrinol; 1997 Jun; 11(6):657-66. PubMed ID: 9171229
[TBL] [Abstract][Full Text] [Related]
16. Modulation of transcription parameters in glucocorticoid receptor-mediated repression.
Sun Y; Tao YG; Kagan BL; He Y; Simons SS
Mol Cell Endocrinol; 2008 Nov; 295(1-2):59-69. PubMed ID: 18583028
[TBL] [Abstract][Full Text] [Related]
17. Agonist-triggered modulation of the activated and silent state of the vitamin D(3) receptor by interaction with co-repressors and co-activators.
Herdick M; Carlberg C
J Mol Biol; 2000 Dec; 304(5):793-801. PubMed ID: 11124027
[TBL] [Abstract][Full Text] [Related]
18. Functional analyses of an LXXLL motif in nuclear receptor corepressor (N-CoR).
Loinder K; Söderström M
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):191-6. PubMed ID: 15336696
[TBL] [Abstract][Full Text] [Related]
19. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.
Gee AC; Carlson KE; Martini PG; Katzenellenbogen BS; Katzenellenbogen JA
Mol Endocrinol; 1999 Nov; 13(11):1912-23. PubMed ID: 10551784
[TBL] [Abstract][Full Text] [Related]
20. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
Berrevoets CA; Umar A; Trapman J; Brinkmann AO
Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
